Glutaric acidemia type II
آخر تحديث 26 يوليو 2023
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- Ask Patient
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
Glutaric acidemia type II is an inherited disorder that interferes with the body's ability to break down proteins and fats to produce energy. Incompletely processed proteins and fats can build up in the body and cause the blood and tissues to become too acidic (metabolic acidosis).
اختيارات الفيديو لـ الحالات الوراثيةمكتبة الفيديو
الوصف
Glutaric acidemia type II is an inherited disorder that interferes with the body's ability to break down proteins and fats to produce energy. Incompletely processed proteins and fats can build up in the body and cause the blood and tissues to become too acidic (metabolic acidosis).
Glutaric acidemia type II usually appears in infancy or early childhood as a sudden episode called a metabolic crisis, in which acidosis and low blood glucose (hypoglycemia) cause weakness, behaviour changes such as poor feeding and decreased activity, and vomiting. These metabolic crises, which can be life-threatening, may be triggered by common childhood illnesses or other stresses.
In the most severe cases of glutaric acidemia type II, affected individuals may also be born with physical abnormalities. These may include brain malformations, an enlarged liver (hepatomegaly), a weakened and enlarged heart (dilated cardiomyopathy), fluid-filled cysts and other malformations of the kidneys, unusual facial features, and genital abnormalities. Glutaric acidemia type II may also cause a characteristic odor resembling that of sweaty feet.
Some affected individuals have less severe symptoms that begin later in childhood or in adulthood. In the mildest forms of glutaric acidemia type II, muscle weakness developing in adulthood may be the first sign of the disorder.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
Electron transfer flavoprotein deficiency
EMA
ETFA deficiency
ETFB deficiency
ETFDH deficiency
Ethylmalonic-adipicaciduria
GA II
Glutaric acidemia, type 2
Glutaric aciduria, type 2
MAD
MADD
Multiple acyl-CoA dehydrogenase deficiency
Multiple FAD dehydrogenase deficiency
Related patient information and medicines

Patient information leaflet
علاج مرض السكري من النوع 2
If a high blood sugar level is brought down to a normal level, your symptoms will ease and your risk of long-term complications will be much lower. Managing type 2 diabetes الحفاظ على blood sugar (glucose) well controlled is key to reducing your risk of long-term complications such as heart, kidney or eye problems. ...de Lixisenatide for.

Patient information leaflet
السكري من النوع 2
Type 2 diabetes can occur at any age, including during childhood, but it occurs mainly in people aged over 40. The first-line treatment is diet, weight control and physical activity. Other treatments include reducing blood pressure if it is high, lowering high cholesterol levels, and also... This is called insulin resistance. You can learn more.

Patient information leaflet
نظام غذائي لمرضى السكري من النوع 2
The first-line treatment for type 2 diabetes involves making changes to your lifestyle, through diet, weight control and physical activity. Regular check-ups السكري من النوع 2 and medication for diabetes (whether in tablet or injection form) definitely aren't the only way to control your blood sugar (glucose) levels. Dr Partha Kar The first-line.

Patient information leaflet
اضطرابات تخزين الجليكوجين
Symptoms include weakness, tiredness and low blood ... Newer treatment possibilities provide hope for an improved outlook (prognosis). Most people with a glycogen storage disorder respond well to treatment. However, type II (infantile Pompe's disease) can be difficult to treat and can affect life expectancy. What is glycogen. Your body needs the.

Patient information leaflet
اختبار بقعة الدم لحديثي الولادة
Mothers of all newborn babies are offered testing for certain rare but serious health conditions by testing blood taken from the baby's heel. This is the blood spot screening programme and it is also known as the heel prick test. Also, a sud... All four devolved nations of the United Kingdom now offer screening for four other serious, but.

Patient information leaflet
مرض الكلى السكري
Diabetic kidney disease is common. Around 30 to 40% of people with diabetes (both type 1 diabetes Type 1 diabetes and type 2 diabetes Type 2 diabetes ) develop some form of diabetic kidney disease. مرض الكلى السكري is actually the most common cause of فشل كلوي in the UK. Around one in five people needing dialysis have diabetic kidney.
قراءة إضافية ومراجع
- Glutaric acidemia type II; MedlinePlus, National Library of Medicine.
- Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab. 2008 Jan;93(1):36-9. doi: 10.1016/j.ymgme.2007.09.015. Epub 2007 Oct 31.
- Cornelius N, Frerman FE, Corydon TJ, Palmfeldt J, Bross P, Gregersen N, Olsen RK. Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Hum Mol Genet. 2012 Aug 1;21(15):3435-48. doi: 10.1093/hmg/dds175. Epub 2012 May 18.
- Curcoy A, Olsen RK, Ribes A, Trenchs V, Vilaseca MA, Campistol J, Osorio JH, Andresen BS, Gregersen N. Late-onset form of beta-electron transfer flavoprotein deficiency. Mol Genet Metab. 2003 Apr;78(4):247-9. doi: 10.1016/s1096-7192(03)00024-6.
- Goodman SI, Binard RJ, Woontner MR, Frerman FE. Glutaric acidemia type II: gene structure and mutations of the electron transfer flavoprotein:ubiquinone oxidoreductase (ETF:QO) gene. Mol Genet Metab. 2002 Sep-Oct;77(1-2):86-90. doi: 10.1016/s1096-7192(02)00138-5.
- Olsen RK, Andresen BS, Christensen E, Bross P, Skovby F, Gregersen N. Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency. Hum Mutat. 2003 Jul;22(1):12-23. doi: 10.1002/humu.10226.
- Olsen RK, Olpin SE, Andresen BS, Miedzybrodzka ZH, Pourfarzam M, Merinero B, Frerman FE, Beresford MW, Dean JC, Cornelius N, Andersen O, Oldfors A, Holme E, Gregersen N, Turnbull DM, Morris AA. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain. 2007 Aug;130(Pt 8):2045-54. doi: 10.1093/brain/awm135. Epub 2007 Jun 20.
- Olsen RK, Pourfarzam M, Morris AA, Dias RC, Knudsen I, Andresen BS, Gregersen N, Olpin SE. Lipid-storage myopathy and respiratory insufficiency due to ETFQO mutations in a patient with late-onset multiple acyl-CoA dehydrogenation deficiency. J Inherit Metab Dis. 2004;27(5):671-8. doi: 10.1023/b:boli.0000042986.10291.e9.
- Purevjav E, Kimura M, Takusa Y, Ohura T, Tsuchiya M, Hara N, Fukao T, Yamaguchi S. Molecular study of electron transfer flavoprotein alpha-subunit deficiency in two Japanese children with different phenotypes of glutaric acidemia type II. Eur J Clin Invest. 2002 Sep;32(9):707-12. doi: 10.1046/j.1365-2362.2002.01045.x.
- Schiff M, Froissart R, Olsen RK, Acquaviva C, Vianey-Saban C. Electron transfer flavoprotein deficiency: functional and molecular aspects. Mol Genet Metab. 2006 Jun;88(2):153-8. doi: 10.1016/j.ymgme.2006.01.009. Epub 2006 Feb 28.
- Takken T, Custers J, Visser G, Dorland L, Helders P, de Koning T. Prolonged exercise testing in two children with a mild Multiple Acyl-CoA-Dehydrogenase deficiency. Nutr Metab (Lond). 2005 May 20;2(1):12. doi: 10.1186/1743-7075-2-12.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
26 يوليو 2023 | أحدث إصدار
1 Jul 2008 | نُشر في الأصل
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.

